Skin Protein Profile after Major Weight Loss and Its Role in Body Contouring Surgery

José Renato B. Gallo, PhD*
Larissa B. Maschio-Signorini, MSc†
Celso R. B. Cabrал, PhD¶
Debora A. P. de Campos Zucchini, PhD†
Maurício L. Nogueira, PhD¶
Antônio R. Bozola, PhD∥
Patricia M. Cury, PhD**
Alessandra Vidotto, PhD††

Background: Chronic inflammation during morbid obesity significantly alters cutaneous tissue. Large weight loss achieved after bariatric surgery minimizes or halts damage caused by metabolic syndrome, but further deteriorates the clinical condition of skin. Postbariatric skin flaccidity produces major difficulties to plastic surgery. In this study, we analyzed differences in protein composition of the skin between patients with morbid obesity and those after large weight loss and established correlations between differentially expressed proteins and clinical characteristics of postbariatric skin tissue, to improve body contouring surgery techniques.

Methods: Skin fragments were removed from the abdomen of 32 patients, who were allocated into 3 groups: morbidly obese, large weight loss without surgery, and postbariatric surgery. Samples were subjected to proteomic analysis, and the protein profiles of the groups were compared. Six differentially expressed proteins of clinical interest were validated by immunohistochemistry and statistical analysis.

Results: Comparative analyses confirmed differences in protein profile of the skin between morbidly obese and large weight loss groups. A persistent increase in inflammatory markers such as haptoglobin was observed in all groups and decrease in the expression of collagen XIV, which regulates the physical properties of cutaneous tissue, was observed in the postbariatric group.

Conclusions: High expression of haptoglobin associated with the decrease of Collagen XIV, vinculin, and periplakin in the groups after major weight losses, mainly postbariatric, confirm that the inflammatory lesion remains active in the skin and causes changes in its structural organization, with serious repercussions on its clinical characteristics and physical properties. (Plast Reconstr Surg Glob Open 2019;7:e2339; doi: 10.1097/GOX.0000000000002339; Published online 19 August 2019.)

Disclosure: This work and Dr. Gallo received financial support from Centro de Estudos em Cirurgia Plástica (CE-Plástica), a non-profit organization who works promoting aid in the teaching of plastic surgery at the Hospital de Base and Faculdade de Medicina de São José do Rio Preto. The resources were used exclusively in the purchase of materials and inputs necessary for the realization of the research. Dr. Cabral is supported by a CNPq grant (grant no. 447964/2014-3).
Large weight loss and complete remission or improvement of clinical and laboratory parameters of the main comorbidities associated with metabolic syndrome have made bariatric surgery the most effective therapeutic modality for morbid obesity. However, in contrast to typical metabolic diseases, postbariatric surgery skin shows clear signs of clinical deterioration, such as reduced elasticity and turgor proportional to the progression of weight loss.

Previous studies have examined the clinical characteristics, histological organization, and molecular composition of skin. They revealed important differences between normal cutaneous tissue, in obesity and great weight loss; however, the characteristics of postbariatric skin requires further analysis.

Knowledge about dynamic behavior of collagen and other proteins in the cutaneous tissue, capable of changing its structure, interactions with other proteins, and biological functions in response to changes in local and systemic conditions of the organism may reveal the causes of clinical differences in skin among these groups of patients. Proteomic analysis and immunohistochemistry (IHC) enable determination of the protein composition of the skin and allow for comparisons between groups of patients.

The differences observed between the flaccidity of postbariatric surgery skin and the skin after major weight loss without surgery are not well understood at the molecular level. Clinical observation revealed significantly different characteristics and behaviors over time, generating important responses in the results of body contouring surgeries practiced in these 2 groups of patients.

In this study, we examined the differences in the protein profiles of the skin in 3 groups of patients: morbid obesity, after major weight loss without surgery and postbariatric, and established correlations between differentially expressed proteins and the clinical characteristics of cutaneous tissue after bariatric surgery. The understanding of the protein alterations that occur in the postbariatric skin can generate adjuvant clinical treatments able to improve the quality of the skin before and after the body contouring surgeries, with consequent improvement of its results.

**PATIENTS AND METHODS**

Thirty-two female white patients, aged 18–53 years (average, 34 years) and diagnosed with morbid obesity (BMI ≥ 40 kg/m²), were selected. All patients had at least one year of weight stabilization to undergo body contouring surgery.

Patients were allocated to 3 groups according to clinical criteria (Table 1). In the large weight loss groups (B and C), only patients who lost at least 60% of excess weight—considering the excess weight as the difference between the maximum weight recorded and the ideal weight with BMI fixed at 25 kg/m²—were included.

Smokers, patients with diabetes mellitus, thyroid diseases, and patients with previous abdominal plastic surgeries were excluded.

Skin samples containing the epidermis and dermis were obtained from the anterior region of the abdomen.

---

**Table 1. Composition of Study Groups**

| Group | No. Patients | Proposed Surgery |
|-------|--------------|------------------|
| Group A (morbidly obese) | 12 | RYGB |
| Group B (large weight loss without surgery) | 8 | Classic abdominoplasty or modified vertical abdominoplasty |
| Group C (large weight loss postbariatric surgery) | 12 | Modified vertical abdominoplasty |

RYGB indicates Roux-en-Y gastric bypass.

**Proteomic Analysis**

Frozen skin fragments were solubilized and the tissue proteins extracted and then quantified by the Bradford method. To minimize individual differences, the proteins were grouped into 5 sample pools with equivalent amount of proteins extracted from each skin fragment (Table 2).

The 5 protein pools were analyzed by 1-dimensional electrophoresis (1DE) and 2-dimensional electrophoresis (2DE). All 1DE gel slices and spots of interest were removed from the 2DE gels, subjected to trypsin digestion, and the resulting peptides were identified by mass spectrometry (MS) using electrospray ionization/quadrupole time-of-flight MS. MS data analysis was performed by bioinformatics searches with the Mascot Database (http://www.matrixscience.com) tool in human databases. Comparative analyses of the proteins identified by 1DE were performed using Scaffold 3.3.3 software (Proteome Software, Inc., Portland, Ore.).

After comparing the pools of each group, qualitative and quantitative differences in the expression of proteins with clinically relevant biological roles in this study (http://www.ncbi.nlm.nih.gov/pubmed/, http://www.ncbi.nlm.nih.gov/pubmed?gene, http://www.uniprot.org) were used to select 6 proteins for IHC validation.

**Validation by IHC**

The skin fragments reserved for IHC were fixed in formalin and embedded in paraffin, after gradual thawing. Twenty histological sections (3 μm) for each sample were used for slide preparation.

For antigen-antibody reactions, deparaffinization, rehydration, and endogenous peroxidase blocking were

---

**Table 2. Composition and Characteristics of Protein Pools of the Samples**

| Pool | No. of Samples | Protein Mass | Clinical Characteristics of the Sample | Study Group |
|------|---------------|--------------|--------------------------------------|-------------|
| I    | 6             | 3,000 μg     | Morbidly obese for <35 years           | A           |
| II   | 6             | 3,000 μg     | Morbidly obese for ≥35 years           | A           |
| III  | 8             | 3,000 μg     | Large weight loss without surgery      | B           |
| IV   | 6             | 3,000 μg     | Postbariatric surgery for ≥35 years    | C           |
| V    | 6             | 3,000 μg     | Postbariatric surgery for <35 years    | C           |
used to prepare the samples. Antigenic recovery was conducted according to the procedures in the primary antibody (AB) datasheets (Table 3).

Samples were analyzed under a light microscope with 10× and 40× objectives. Analysis and scoring were conducted by the same pathologist (Table 4).

**Statistical Analysis**

Statistical tests were performed to compare groups B (large weight loss without surgery) and C (postbariatric surgery). The hypothesis of independence (H₀) or some dependency (H₁) was tested between the method of weight loss and expression of the protein of interest in the skin.

The sample size of this study was small; additionally, clinical data were converted into numerical values. Thus, Bayesian method of comparison of models was conducted; this is based on Bayes factor (BF₁₀) 31,32 and is analogous to the likelihood ratio test calculations, which were found to be inadequate for statistical analysis in this study (Table 5). 32

The IHC results for groups B and C were organized into tables with 2 variables: method of weight loss (X) and score of the protein of interest (Y).

In this study, the hypothesis (H₁) tested, or model M₁, was that the presence or absence of bariatric surgery in patients after large weight loss is related to the expression of proteins of interest in the skin samples in these 2 groups of patients.

The package LearnBayes in software R (R Core Team, 2019, Austria) 33 was used to calculate BF₁₀. Statistical analyses were restricted to comparisons between groups B and C because of the specific clinical interest of these groups for plastic surgery.

| Antibody                     | Specificity       | Dilution | Buffer       | Positive Control       | Primary AB Brand            |
|------------------------------|-------------------|----------|--------------|------------------------|-----------------------------|
| Anticollagen XIV (Anti-COLXIV) | Polyclonal (rabbit) | 1:25     | Citrate (pH 6) | Human cardiac tissue   | Lifespan (LS Cl19470)      |
| Antivinculin                 | Monoclonal (mouse) | 1:2,000  | Citrate (pH 6) | Fibroblasts            | ABCAM (ab 1194)            |
| Antiperiplakin               | Monoclonal (rabbit) | 1:900    | Citrate (pH 6) | Human skin             | ABCAM (ab 131269)          |
| Antiannexin V                | Polyclonal (rabbit) | 1:400    | Citrate (pH 6) | Cutaneous melanoma     | ABCAM (ab 14196)           |
| Antihtapoglobin             | Monoclonal (mouse) | 1:100    | Citrate (pH 6) | Lung cancer            | ABCAM (ab 15429)           |
| Anti-alpha-1 anti-trypsin    | Polyclonal (rabbit) | 1:2,000  | Citrate (pH 6) | Human tonsil           | ABCAM (ab 49088)           |

**RESULTS**

**Proteomic Analysis**

MS was analyzed using the Mascot Distiller and Daemon (Mascot Software, Boston, MA, USA) and Scaffold 3.3.3 softwares, which identified 113 proteins in 1DE and 100 proteins in 2DE. Based on these results, the skin profile of each group was established. Figures 1 and 2 show the results of the sodium dodecyl sulfate–polyacrylamide gel electrophoresis (SDS-PAGE), and Figure 3 shows the results of the Scaffold featured 113 identified proteins in 1DE.

Among the proteins identified in 1DE, analyses with Scaffold 3.3.3 using predetermined parameters, protein threshold ≥95% and fold-change ≥2.0 or ≤0.4, revealed 28 differentially expressed proteins in the skin samples of group A (morbidly obese) when compared with patients with large weight loss without bariatric surgery (group B). Comparison of groups A and C (postbariatric) revealed 23 proteins with differential expression. Comparison of patients’ skin protein profiles after large nonsurgical and postbariatric weight loss (groups B and C) demonstrated that 23 proteins were differentially expressed. The main differences in skin protein composition between groups are presented in Tables 6 and 7.

Collagen XIV (COL14A1), haptoglobin (HP), periplakin (PPL), vinculin (VCL), annexin A5, and alpha-1-antitrypsin were selected for IHC validation tests because they showed differences in expression between groups and because of the high clinical relevance of their biological functions (http://www.ncbi.nlm.nih.gov/pubmed/), (http://www.ncbi.nlm.nih.gov/pubmed/gene, http://www.uniprot.org; Table 8).

**Validation by IHC and Statistical Analysis**

The sample staining score for COL14A1 confirmed the proteomic analysis data, showing higher expression in the skin of patients with large weight loss without surgery (group B), compared with the postbariatric group (group C) (Figs. 4, 5). The BF₁₀ of 3.83 supports the model of dependence (M₁) between the weight loss method and expression of COL14A1 in patient skin; there was a significant difference in the levels of this protein in the tissue between groups B and C.

Most samples stained for PPL showed low or zero scores; however, the highest expression of this protein was observed in samples from group B, and not in those from group C, validating the proteomics data. A BF₁₀ of 1.32 indicated weak support for the model of dependence and revealed the differential expression of PPL in the skin of large weight loss patients in this study.

**Table 3. Information Regarding Primary Antibodies (AB) Used for IHC Validation**

| Antibody                     | Specificity       | Dilution | Buffer       | Positive Control       | Primary AB Brand            |
|------------------------------|-------------------|----------|--------------|------------------------|-----------------------------|
| Anticollagen XIV (Anti-COLXIV) | Polyclonal (rabbit) | 1:25     | Citrate (pH 6) | Human cardiac tissue   | Lifespan (LS Cl19470)      |
| Antivinculin                 | Monoclonal (mouse) | 1:2,000  | Citrate (pH 6) | Fibroblasts            | ABCAM (ab 1194)            |
| Antiperiplakin               | Monoclonal (rabbit) | 1:900    | Citrate (pH 6) | Human skin             | ABCAM (ab 131269)          |
| Antiannexin V                | Polyclonal (rabbit) | 1:400    | Citrate (pH 6) | Cutaneous melanoma     | ABCAM (ab 14196)           |
| Antihtapoglobin             | Monoclonal (mouse) | 1:100    | Citrate (pH 6) | Lung cancer            | ABCAM (ab 15429)           |
| Anti-alpha-1 anti-trypsin    | Polyclonal (rabbit) | 1:2,000  | Citrate (pH 6) | Human tonsil           | ABCAM (ab 49088)           |

**Table 4. Analysis of IHC Validation**

| Staining Pattern Observed | Score (in Crosses) | Numerical Value |
|---------------------------|--------------------|-----------------|
| Absence of staining       | No score           | 0               |
| Weak or focally positive staining | +                 | 1               |
| Clear positive and distributed staining | ++                | 2               |
| Strongly positive and diffuse staining | +++               | 3               |

**Table 5. Values for Interpretation of BF₁₀** 32

| BF₁₀ | Interpretation            |
|------|---------------------------|
| <1   | In favor of M₀            |
| Between 1 and 3 | Weakly favorable to M₁   |
| Between 3 and 20 | In favor of M₁         |
| Between 20 and 150 | Strong evidence in favor of M₁ |
| ≥150 | Strong evidence in favor of M₁ |
All samples exhibited staining for annexin A5, reflecting the widespread presence of this protein in cutaneous tissue. The analysis revealed higher scores in the group of large weight loss patients without surgery compared with the postbariatric surgery group, confirming the proteomics data. These differences were significant with a BF$_{10}$ of 2.74, indicating weak support for the dependence model tested.

The slides with samples marked for HP and alpha-1-anti-trypsin displayed weak or null staining, but positive samples were detected in all groups. No significant differences were observed in the comparisons between groups.

The IHC results for VCL were unlike those obtained with the proteomic analysis, displaying greater staining in samples from large weight loss groups when compared with the group of patients with morbid obesity. Statistical analysis supported the independence model with a BF$_{10}$ of 0.74.

**DISCUSSION**

The increase in the number of patients with large weight loss has generated demand for plastic surgery. Technical innovations have been proposed to achieve better results in the redefinition of body contour\textsuperscript{29,42–46}; however, the clinical characteristics of postbariatric skin, unlike normal cutaneous tissue, represent major challenges for the development of these new surgical procedures.

The anatomy, histology, and molecular composition of normal skin\textsuperscript{47–49} as well as changes in cutaneous tissue in individuals with obesity have been described and reviewed in detail.\textsuperscript{11,12} However, knowledge of processes occurring in the skin after major weight loss remains incomplete.

The use of proteomics\textsuperscript{19} and IHC\textsuperscript{21} enabled comparative analysis of skin protein composition in the morbid obesity and after massive weight loss groups. The differences between the protein profiles in the cutaneous tissue of patients with large weight loss without surgery (group B) compared with the postbariatric surgery group (group C) confirmed the need for further analysis of undesired consequences after bariatric surgery and limitations of body contour techniques.

Identification and analysis of the biological roles of proteins such as HP\textsuperscript{50–54} (acute phase protein) and structural proteins such as Collagen XIV\textsuperscript{34} and VCL\textsuperscript{41} may pave the way for novel treatment protocols that seek to prevent the progression of inflammatory skin lesions and may promote replacement of essential elements to the maintenance of the physical and mechanical characteristics of the skin after major weight losses.

The profile of HP, a biomarker of inflammation and oxidative stress,\textsuperscript{50,51} indicated that systemic inflammatory
Fig. 2. Sodium dodecyl sulfate–polyacrylamide gel electrophoresis (SDS-PAGE) GE (12.5%), stained with Coomassie blue, in 2DE of pool III (patients after major weight loss without surgery). Highlighted, spots selected for digestion with trypsin and protein identification.

Fig. 3. Parameters used in Scaffold 3.3.3 software to identify 1DE proteins from databases. The minimum percentage of applied reliability (min protein = 95%) and 113 proteins identified are highlighted.
injury extends to the cutaneous tissue of patients with morbid obesity (group A) and remains active even after large weight loss (groups B and C). Thus, HP is one of the factors involved in the progressive worsening of clinical conditions and histological changes observed in the cutaneous tissue of postbariatric patients.13,14,52–54 Treatments capable of combating the inflammatory process on the skin of patients undergoing weight loss can reduce the deleterious effects of HP on collagenases and elastases, reducing foci of tissue fibrosis,52–54 preserving skin elasticity,22 and improving the clinical conditions of body contouring surgeries.

Changes in the metabolism of collagen, initiated by obesity,11,55 remain present after weight loss and are key to understanding the processing occurring in the skin of patients with weight loss after bariatric surgery. COL14A1, a fibril-associated collagen with an interrupted triple helix, regulates fibrillogenesis and coordinates the structural organization of collagen types I, III, and V. This protein controls the associations between extracellular matrix (ECM) fibers and keratinocytes and skin fibroblasts.34,56–58 Therefore, the structural composition and molecular organization of collagen in cutaneous tissue postbariatric surgery patients become disordered, which differs from the processes in the skin of large weight loss patients without surgery. Thus, the challenges of postbariatric body contouring surgery extend beyond the technical development required for removing large quantities of excess skin.

In this context, PPL37,38,59 and VCL40,41,60–63 2 other proteins that function in tissue architecture and regulate the

Table 6. Main Proteins Differentially Expressed in the Skin, with Comparisons Between Morbidly Obese (A) and Large Weight Loss Groups (B and C)

| Universal Protein Database (UNIPROT)/Gene Accession Identification (ID) | Protein Name       | Gene Symbol | Groups Compared | Fold-Change (Greater Among the Pools) |
|--------------------------------------------------------------------------|--------------------|-------------|-----------------|-------------------------------------|
| P00738/3240 Haptoglobin                                                  | HP                 | A × B       | 70.0            |
| P00738/3240 Haptoglobin                                                  | HP                 | A × C       | 6.0             |
| P18206/7414 Vinculin                                                    | VCL                | A × B       | 30.0            |
| P18206/7414 Vinculin                                                    | VCL                | A × C       | 3.0             |
| P21335/2316 Filamin A                                                   | FLNA               | A × B       | 6.0             |
| P21335/2316 Filamin A                                                   | FLNA               | A × C       | 6.0             |
| P02458/1280 Collagen II–alpha-1                                         | COL2A1             | A × B       | 14.0            |
| P02458/1280 Collagen II–alpha-1                                         | COL2A1             | A × C       | 2.8             |
| Q07507/1805 Dermatopontin                                               | DPT                | A × B       | 4.0             |
| F16422/4072 Epithelial cell adhesion molecule                            | EPCAM              | A × C       | 3.8             |

Table 7. Main Proteins Differentially Expressed in the Skin, with Comparisons of Large Weight Loss Without Surgery (B) and Postbariatric Surgery (C) Groups

| UNIPROT/Gene Accession ID | Protein Name                        | Gene Symbol | Groups Compared | Fold-Change (Greater Among the Pools) |
|---------------------------|-------------------------------------|-------------|-----------------|-------------------------------------|
| Q05707/7373              | Collagen alpha-1 (XIV) chain        | COL14A1     | B × C           | 7.0                                |
| P02458/1280              | Collagen alpha-1 (II) chain         | COL2A1      | B × C           | 0.2                                |
| O60437/5493              | Periplakin                           | PPL         | B × C           | 3.0                                |
| P07951/7169              | Tropomyosin beta chain              | TPM2        | B × C           | 4.0                                |
| P35579/4627              | Myosin-9                             | MYH9        | B × C           | 8.0                                |
| P58107/83481             | Epilakin                             | EPPK1       | B × C           | 0.2                                |

Table 8. List of 6 Proteins Selected for Validation Testing by IHC

| UNIPROT/Gene Accession ID | Protein Name | Gene Symbol | Groups Compared | Fold-Change | Main Function in Skin |
|---------------------------|--------------|-------------|-----------------|-------------|-----------------------|
| Q05707/7373              | Collagen alpha-1 (XIV) chain        | COL14A1     | B × C           | 7.0         | Regulation of intracellular fibrilogenesis34 |
| P00738/3240              | Haptoglobin  | HP          | A × B and A × C | 70.0 and 6.0 | Inflammation marker (APP)35 |
| P01009/5265              | Alpha-1-antitrypsin                   | SERPIN1    | A × B           | 0.2         | Inflammation marker (APP), Inhibition of neutrophil elastase36 |
| O60437/5493              | Periplakin                               | PPL         | B × C           | 3.0         | Cytoskeletal connections (intermediate filaments, junctional complexes and desmosomes)37,38 |
| P08758/308               | Annexin A5                               | ANXA5       | B × C           | B > C (2DE) | Regulation of apoptosis (PCD)39 |
| P18206/7414              | Vinculin                                | VCL         | A × B           | 30.0        | Cell-ECM (focal adhesions) and intercellular connections (junctional complexes)40,41 |

UNIPROT, Universal Protein Database; ID, identification; AAP, acute phase protein; PCD, programmed cell death.
mechanical properties of cutaneous tissue and cell adhesion, also displayed lower expression in the skin of patients after bariatric surgery (group C). PPL is responsible for associations between elements of the cellular skeleton, particularly the cytoplasmic intermediate filaments and junctional complexes (JCs) of the plasma membrane. As a structural component of the corneal envelope and desmosomes in keratinocytes, PPL plays a key role in the protection and resistance of cutaneous tissue. VCL is an essential protein component in the structure and function of focal adhesions (FAs) and JC. FAs transmit stimuli between cytoskeleton actin and ECM proteins, including collagen, to modulate the physical properties of cutaneous tissue. The JCs function as intercellular adhesion structures. The low expression of VCL in the skin after major weight loss reduced FA and JC levels, worsening flaccidity. The lower tissue availability of PPL and VCL severely impaired the regulation of rigidity, both in the static stabilization force and transmission of intercellular contractile forces, and between cells and the ECM.

Taken together, differences in the expression of COL14A1, PPL, and VCL, which are proteins directly related to the structural composition and mechanical properties of cutaneous tissue, make up the set of molecular alterations responsible for the distinct clinical characteristics observed between skin flaccidity in postbariatric surgery.
patients and after major weight loss without surgery. Thus, this group of patients requires different and broader therapeutic planning, including managing expectations related to the final aesthetic result based on the specific clinical characteristics of the skin, protocols of preoperative protein supplementation capable of improving the clinical conditions of the skin, development and application of techniques that allow greater withdrawal of excess skin, and understanding of changes in the skin’s protein profile.

CONCLUSIONS

The high expression of HP associated with the decrease of Collagen XIV, VCL, and PPL in the groups after major weight losses, mainly postbariatric, confirms that the inflammatory lesion remains active in the skin and causes changes in its structural organization, with serious repercussions on its clinical characteristics and physical properties. Therapeutic protocols capable of combining anti-inflammatory actions and specific protein supplementation may improve the clinical conditions of the skin after major weight loss, impacting the results of the body contouring surgery.

Alessandra Vidotto, PhD
Laboratório Multiusuário
Faculdade de Medicina de São José do Rio Preto (FAMERP)
Avenida Brigadeiro Faria Lima 5416
Vila São Pedro, São José do Rio Preto
SP 15090-000, Brazil
E-mail: alessandarvidotto@yahoo.com.br

ACKNOWLEDGMENTS

The authors thank the Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP), Rede Proteoma do Estado de São Paulo (Grants FAPESP no. 2004/14846-0/FINEP no. 01.07.0290.00), Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES) and Conselho Nacional de Pesquisa (CNPq) for financial support and fellowships. We acknowledge the Mass Spectrometry at Brazilian Biosciences National Laboratory (LNBio), CNPEN, Campinas, Brazil, for their support with the use of NanoAcquity Ultra Performance LC coupled with nanoelectrospray source on Q-TOF Ultima mass spectrometer (Waters).

REFERENCES

1. Agarwal S, Shenaq D, Teven CM, et al. Body contouring after obesity surgery is associated with a weight loss benefit among patients. J Plast Reconstr Aesthet Surg. 2017;70:1186–1190.
2. Abbed TM, Gonzalez-Heredia R, Sanchez-Johnsen L, et al. Impact of abdominal lipoectomy on post-sleeve gastrectomy surgery weight loss. Ann Plast Surg. 2017;79:495–497.
3. Wiser I, Avinoha E, Ziv O, et al. Body contouring surgery decreases long-term weight regain following laparoscopic adjustable gastric banding: a matched retrospective cohort study. J Plast Reconstr Aesthet Surg. 2016;69:1490–1496.
4. Wiser I, Heller L, Spector C, et al. Body contouring procedures in three or more anatomical areas are associated with long-term body mass index decrease in massive weight loss patients: a retrospective cohort study. J Plast Reconstr Aesthet Surg. 2017;70:1181–1185.
5. Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science. 1993;259:87–91.
6. Hotamisligil GS. Inflammation and metabolic disorders. Nature. 2006;444:860–867.
7. Silva KR, Côrtes I, Liechicki S, et al. Characterization of stromal vascular fraction and adipose stem cells from subcutaneous, preperitoneal and visceral morbidly obese human adipose tissue depots. PLoS One. 2017;12:e0174115.
8. Lumeng CN, Saltiel AR. Inflammatory links between obesity and metabolic disease. J Clin Invest. 2011;121:2111–2117.
9. Buchwald H, Avidor Y, Braunwald E, et al. Bariatric surgery: a systematic review and meta-analysis. JAMA. 2004;292:1724–1737.
10. Wolf AM, Beisiegel U. The effect of loss of excess weight on the metabolic risk factors after bariatric surgery in morbidly and super-obese patients. Obes Surg. 2007;17:910–919.
11. Black MM, Bottoms E, Shuster S. Skin collagen and thickness in simple obesity. Br Med J. 1971;4:149–150.
12. Shipman AR, Millington GW. Obesity and the skin. Br J Dermatol. 2011;165:745–750.
13. Migliori FC, Robello G, Ravetti JL, et al. Histological alterations following bariatric surgery: pilot study. Obes Surg. 2008;18:1305–1307.
14. Light D, Arvanitis GM, Abramson D, et al. Effect of weight loss after bariatric surgery on skin and the extracellular matrix. Plast Reconstr Surg. 2010;125:343–351.
15. Veiga DF, Bussolaro RA, Kobayashi EY, et al. Glycosaminoglycans of abdominal skin after massive weight loss in post-bariatric female patients. Obes Surg. 2011;21:774–782.
16. Halawi A, Abiad F, Abbas O. Bariatric surgery and its effects on the skin and skin diseases. Obes Surg. 2015;25:408–413.
17. Braun P, Ginzas AC. History of protein-protein interactions: from egg-white to complex networks. Proteomics. 2012;12:1478–1498.
18. Huang CM, Elmets CA, van Kampen KR, et al. Prospective highlights of functional skin proteomics. Mass Spectrom Rev. 2005;24:647–660.
19. Brandacher G, Golderer G, Kienzl K, et al. Potential applications of global protein expression analysis (proteomics) in morbid obesity and bariatric surgery. Obes Surg. 2008;18:905–910.
20. Barbosa EB, Vidotto A, Polachini GM, et al. Proteomics: methodologies and applications to the study of human diseases. Rev Assoc Med Bras (1992). 2012;58:366–375.
21. Jambhekar NA, Chaturvedi AC, Madur BP. Immunohistochemistry in surgical pathology practice: a current perspective of a simple, powerful, yet complex, tool. Indian J Pathol Microbiol. 2008;51:2–11.
22. Fearmonti RM, Blanton M, Bond JE, et al. Changes in dermal histomorphology following surgical weight loss versus diet-induced weight loss in the morbidly obese patient. Ann Plast Surg. 2012;68:507–512.
23. Kopelman PG. Obesity as a medical problem. Nature. 2000;404:635–643.
24. Adams KA, Schatzkin A, Harris TB, et al. Overweight, obesity, and mortality in a large prospective cohort of persons 50 to 71 years old. N Engl J Med. 2006;355:763–778.
25. Switzer NJ, Mangat HS, Karmali S. Current trends in obesity: body composition assessment, weight regulation, and emerging techniques in managing severe obesity. J Intervent Gastroenterol. 2013;3:34–36.
26. Fobi MA, Lee H, Holness R, et al. Gastric bypass operation for obesity. World J Surg. 1998;22:925–935.
27. Capella JF, Capella RF. An assessment of vertical banded gastroplasty-Roux-en-Y gastric bypass for the treatment of morbid obesity. Am J Surg. 2002;183:117–123.
28. Bozola AR, Psillakis JM. Abdominoplasty: a new concept and classification for treatment. Plast Reconstr Surg. 1988;82:983–993.
29. Borud LJ, Warren AG. Modified vertical abdominoplasty in the massive weight loss patient. *Plast Reconstr Surg.* 2007;119:1911–1921; discussion 1922.
30. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. *Anal Biochem.* 1976;72:248–254.
31. Jeffrey H. *Theory of Probability.* Oxford University Press; Oxford, England, UK 1961.
32. Kass R, Raftery A. Bayes factors. *JASA.* 1995;90:773–779.
33. Albert J. *LearnBayes: Functions for Learning Bayesian Inference.* R package version 2.15.1; 2018. R Foundation for Statistical Computing, Vienna, Austria.
34. Ansorge HL, Meng X, Zhang G, et al. Type XIV collagen regulates fibrobligenesis: premature collagen fibril growth and tissue dysfunction in null mice. *J Biol Chem.* 2009;284:8427–8438.
35. Xia LX, Xiao T, Chen HD, et al. Regulation of haptoglobin expression in a human keratinocyte cell line HaCaT by inflammatory cytokines and dexamethasone. *Chin Med J (Engl).* 2008;121:730–734.
36. Hunt JM, Tuder R. Alpha 1 anti-trypsin: one protein, many functions. *Curr Mol Med.* 2004;2:669–681.
37. Butmaru CA, Kanitakis J. Structure of normal human skin. *Eur J Dermatol.* 2002;12:II–IV.
38. Ruhrberg C, Hajibagheri MA, Parry DA, et al. Periplakin, a novel component of cornified envelopes and desmosomes that belongs to the plakin family and forms complexes with envoplakin. *J Cell Biol.* 1997;139:1835–1849.
39. Munoz LE, Frey B, Pausch F, et al. The role of annexin A5 in the modulation of the immune response against dying and dead cells. *Curr Mol Med.* 2002;12:II–IV.
40. Berthod F, Germain L, Guignard R, et al. Differential expression of cytoskeletal architecture. *Curr Opin Genet Dev.* 1997;7:392–397.
41. Carisey A, Ballestrem C. Vinculin, an adapter protein in control of cell adhesion formation by direct interactions with talin and actin. *Eur J Cell Biol.* 2011;90:157–163.
42. Carisey A, Tsang R, Greiner AM, et al. Vinculin regulates the reassociation of keratin filaments and may modulate extracellular matrix deformability. *J Biol Chem.* 1994;269:28193–28199.
43. Wälchli C, Koch M, Chiquet M, et al. Tissue-specific expression of the fibril-associated collagens XII and XIV, *J Cell Sci.* 1994;107(pt 2):669–681.
44. Berthod F, Germain L, Guignard R, et al. Differential expression of collagens XII and XIV in human skin and in reconstructed skin. *J Invest Dermatol.* 1997;108:737–742.
45. Leung CL, Green KJ, Liem RK. Plakin: a family of versatile cytolinker proteins. *Trends Cell Biol.* 2002;12:37–45.
46. Diez G, Kollmannsberger P, Mierke CT, et al. Anchorage of vinculin to lipid membranes influences cell mechanical properties. *Biophys J.* 2009;97:3105–3112.
47. Carisey A, Ballestrem C, Vinculin, an adapter protein in control of cell adhesion signalling. *Eur J Cell Biol.* 2011;90:157–163.
48. Kanitakis J. Anatomy, histology and immunohistochemistry of normal human skin. *Eur J Dermatol.* 2002;12:90–99.
49. Mikesch LM, Aramadakha LR, Moskaluk C, et al. Proteomic anatomy of human skin. *J Proteomics.* 2013;84:190–200.
50. Jelena A, Mirjana M, Desanka B, et al. Haptoglobin and the inflammatory and oxidative status in experimental diabetic rats: antioxidant role of haptoglobin. *J Physiol Biochem.* 2013;69:45–58.
51. Gallo et al. • Proteomics in Body Contouring Surgery
52. Butmaru CA, Kanitakis J. Structure of normal human skin. *Eur J Dermatol.* 2002;12:II–IV.
53. Peifer U, Schmidt H, Einzig H, et al. The role of annexin A5 in the modulation of the immune response against dying and dead cells. *Curr Mol Med.* 2002;12:II–IV.
54. Butmaru CA, Kanitakis J. Structure of normal human skin. *Eur J Dermatol.* 2002;12:II–IV.
55. van Gool J, de Nie I, Smit J, et al. Mechanisms by which acute phase proteins enhance development of liver fibrosis: effects on collagenase and prohyl-l-hydroxylase activity in the rat liver. *Exp Mol Pathol.* 1986;45:160–170.
56. van Gool J, van Vugt H, de Nie I. Acute phase reactants enhance CCH4 induced liver cirrhosis in the rat. *Exp Mol Pathol.* 1986;44:157–168.
57. van Gool J, de Nie I, van Vugt H, et al. Relation between acute-phase proteins and enhanced bleomycin-induced pulmonary fibrosis in the rat. *Exp Mol Pathol.* 1988;49:410–420.
58. Berthod F, Germain L, Guignard R, et al. Differential expression of collagens XII and XIV in human skin and in reconstructed skin. *J Invest Dermatol.* 1997;108:737–742.
59. Leung CL, Green KJ, Liem RK. Plakin: a family of versatile cytolinker proteins. *Trends Cell Biol.* 2002;12:37–45.
60. Mierke CT. The role of vinculin in the regulation of the mechanical properties of cells. *Cell Biochem Biophys.* 2009;53:115–126.
61. Diez G, Kollmannsberger P, Mierke CT, et al. Anchorage of vinculin to lipid membranes influences cell mechanical properties. *Biophys J.* 2009;97:3105–3112.
62. Carisey A, Ballestrem C, Vinculin, an adapter protein in control of cell adhesion signalling. *Eur J Cell Biol.* 2011;90:157–163.
63. Carisey A, Tsang R, Greiner AM, et al. Vinculin regulates the recruitment and release of core focal adhesion proteins in a force-dependent manner. *Curr Biol.* 2013;23:271–281.
64. Humphries JD, Wang P, Streluli C, et al. Vinculin controls focal adhesion formation by direct interactions with talin and actin. *J Cell Biol.* 2007;179:1043–1057.